Mov Disord Vol 34, Suppl 2 Archives - Page 213 of 217 - MDS Abstracts

2019 International Congress
Plasma membrane Ca2+ Atpase 1 as a candidate to mediate the degeneration of dopaminergic neurons by inflammation in Parkinson’s disease
B. Erhardt, MS. Marcora, A. Delella Ezcurra, J. Casabona, R. Tarelli, L. Frenkel, P. Bochicchio, D. Bodin, B. Silva, V. Cavaliere Candedo, MI. Farías, C. Ferrari, M. Allo, C. Höcht, A. Chernomoretz, E. Castaño, MC. Leal, F. Pitossi (Capital Federal, Argentina)
Objective: To identify genes involved in the degeneration of the dopaminergic neurons (DN) of the substantia nigra (SN) by inflammation. Background: Parkinson’s disease (PD) is…
2019 International Congress
Study on the effect of levodopa administration on serum zinc levels in Parkinson’s disease patients
H. Matsuyama, K. Matsuura, H. Ishikawa, Y. Hirata, N. Kato, A. Niwa, Y. Narita, H. Tomimoto (Tsu, Japan)
Objective: Since zinc-chelating action of levodopa has been reported in the past, we measured serum zinc level in patients with Parkinson's disease (PD) at our…
2019 International Congress
STAT-ON: a Wearable Inertial System to Objectively Evaluate Motor Symptoms in Parkinson’s Disease
D. Rodriguez-Martin, C. Pérez-López, A. Samà, M. Pié, A. Català, J. Cabestany, A. Rodríguez-Molinero (Vilanova I Geltrú, Spain)
Objective: We present a wearable inertial system for the evaluation of motor symptoms in Parkinson's Disease. Background: PD is the second neurodegenerative disease affecting to around…
2019 International Congress
The carotid ultrasonography revealed vagus nerve atrophy of the patients with parkinsonism
S. Abe, T. Hirato, H. Saiki (Osaka, Japan)
Objective: This study aims to clarify the compare vagus nerve atrophy with Parkinson’s disease (PD) and other atypical parkinsonism. Background: Although the pathogenesis of the…
2019 International Congress
Spectrum of parkinsonian phenotypes associated with GCH1 mutation.
D. Al-Shorafat, A. Shetty, D. Munoz, A. Fasano, A. Lang (Toronto, ON, Canada)
Objective: To describe the heterogeneity of parkinsonism in patients with GCH1 mutations. Background: Dopa-responsive dystonia (DRD) is an inherited disorder that responds dramatically to levodopa…
2019 International Congress
Longitudinal assessment of genetic determinants of cognitive decline in Parkinson’s disease
M. Bakeberg, A. Jefferson, M. Byrnes, S. Ghosh, F. Mastaglia, R. Stell, J. Kenna, S. Walters, M. Hoes, A. Ford, R. Anderton (Nedlands, Australia)
Objective: This study aimed to investigate the relationships between genetic variants reportedly associated with neurological disease and cognitive decline, in patients with PD over a…
2019 International Congress
The Dutch Parkinson and Microbiome Study (DUPARM): Gut Microbiome Composition of Treatment-Naïve De Novo Parkinson’s Disease Patients
J. Boertien, S. Vander Zee, T. van Laar (Groningen, Netherlands)
Objective: To establish the gut microbiome composition of de novo Parkinson’s disease (PD) patients with no history of dopaminergic medication use. Background: PD is often…
2019 International Congress
Identifying Incident Cases of Neurodegenerative Parkinsonism in a Large Observational At-Risk Cohort: the PPMI study
L. Chahine, K. Kieburtz, M. Brumm, C. Caspell-Garcia, C. Coffey, A. Siderowf, D. Weintraub, C. Tanner, T. Foroud, D. Galasko, B. Mollenhauer, T. Simuni, K. Marek (Pittsburgh, PA, USA)
Objective: To examine the potential of a data-driven approach to identify incident cases of neurodegenerative parkinsonian disorders (PD) in a large observational cohort of individuals…
2019 International Congress
Attentional Intervention to Improve Cognition and Gait in Parkinson’s Disease: Side of Onset Effects
A. Cronin-Golomb, O. Barthelemy, A. Marin, B. Davis, S. Alshuaib, T. Ellis, J. Degutis (Boston, MA, USA)
Objective: To establish whether home-based computerized attentional training would improve cognition, gait, and function in Parkinson’s disease (PD). Background: Impairments in cognition and gait are…
2019 International Congress
Parkinson’s disease and melanoma: a serie of 33 patients
J. Doridam, M. Nader, A. Melin, MF. Avril, E. Maubec, B. Degos (Paris, France)
Objective: The objective of our work was to characterize the clinical features of patients with malignant melanoma (MM) associated with Parkinson’s disease (PD) and to…